Names
Blincyto® BlinatumomabIndications and usage
Blinatumomab is FDA approved for the treatment of adult and pediatric patients one month and older with:
- CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
- Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).
- CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
Side effects needing medical attention
The most common adverse reactions are fever, infusion-related reactions, headache, infection, musculoskeletal pain, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea.